434 related articles for article (PubMed ID: 18249108)
41. P21-activated kinase is required for mitotic progression and regulates Plk1.
Maroto B; Ye MB; von Lohneysen K; Schnelzer A; Knaus UG
Oncogene; 2008 Aug; 27(36):4900-8. PubMed ID: 18427546
[TBL] [Abstract][Full Text] [Related]
42. Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies.
Christoph DC; Schuler M
Expert Rev Anticancer Ther; 2011 Jul; 11(7):1115-30. PubMed ID: 21806334
[TBL] [Abstract][Full Text] [Related]
43. Discovery of thiophene inhibitors of polo-like kinase.
Emmitte KA; Andrews CW; Badiang JG; Davis-Ward RG; Dickson HD; Drewry DH; Emerson HK; Epperly AH; Hassler DF; Knick VB; Kuntz KW; Lansing TJ; Linn JA; Mook RA; Nailor KE; Salovich JM; Spehar GM; Cheung M
Bioorg Med Chem Lett; 2009 Feb; 19(3):1018-21. PubMed ID: 19097784
[TBL] [Abstract][Full Text] [Related]
44. Getting in and out of mitosis with Polo-like kinase-1.
van Vugt MA; Medema RH
Oncogene; 2005 Apr; 24(17):2844-59. PubMed ID: 15838519
[TBL] [Abstract][Full Text] [Related]
45. Choice of Plk1 docking partners during mitosis and cytokinesis is controlled by the activation state of Cdk1.
Neef R; Gruneberg U; Kopajtich R; Li X; Nigg EA; Sillje H; Barr FA
Nat Cell Biol; 2007 Apr; 9(4):436-44. PubMed ID: 17351640
[TBL] [Abstract][Full Text] [Related]
46. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).
Uckun FM; Dibirdik I; Qazi S; Vassilev A; Ma H; Mao C; Benyumov A; Emami KH
Bioorg Med Chem; 2007 Jan; 15(2):800-14. PubMed ID: 17098432
[TBL] [Abstract][Full Text] [Related]
47. Aurora kinases dawn as cancer drug targets.
Sausville EA
Nat Med; 2004 Mar; 10(3):234-5. PubMed ID: 14991042
[No Abstract] [Full Text] [Related]
48. A cryptic hydrophobic pocket in the polo-box domain of the polo-like kinase PLK1 regulates substrate recognition and mitotic chromosome segregation.
Sharma P; Mahen R; Rossmann M; Stokes JE; Hardwick B; Huggins DJ; Emery A; Kunciw DL; Hyvönen M; Spring DR; McKenzie GJ; Venkitaraman AR
Sci Rep; 2019 Nov; 9(1):15930. PubMed ID: 31685831
[TBL] [Abstract][Full Text] [Related]
49. BI 2536-mediated PLK1 inhibition suppresses HOS and MG-63 osteosarcoma cell line growth and clonogenicity.
Morales AG; Brassesco MS; Pezuk JA; Oliveira JC; Montaldi AP; Sakamoto-Hojo ET; Scrideli CA; Tone LG
Anticancer Drugs; 2011 Nov; 22(10):995-1001. PubMed ID: 21822121
[TBL] [Abstract][Full Text] [Related]
50. Modeling the mitotic regulatory network identifies highly efficient anti-cancer drug combinations.
Wu Y; Zhuo X; Dai Z; Guo X; Wang Y; Zhang C; Lai L
Mol Biosyst; 2015 Feb; 11(2):497-505. PubMed ID: 25418836
[TBL] [Abstract][Full Text] [Related]
51. Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC.
Medema RH; Lin CC; Yang JC
Clin Cancer Res; 2011 Oct; 17(20):6459-66. PubMed ID: 22003073
[TBL] [Abstract][Full Text] [Related]
52. Targeting Polo-like kinase in cancer therapy.
Degenhardt Y; Lampkin T
Clin Cancer Res; 2010 Jan; 16(2):384-9. PubMed ID: 20068088
[TBL] [Abstract][Full Text] [Related]
53. Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?
Tsykunova G; Reikvam H; Ahmed AB; Nepstad I; Gjertsen BT; Bruserud Ø
Expert Opin Investig Drugs; 2012 May; 21(5):587-603. PubMed ID: 22424119
[TBL] [Abstract][Full Text] [Related]
54. Small-molecular, non-peptide, non-ATP-competitive polo-like kinase 1 (Plk1) inhibitors with a terphenyl skeleton.
Mita Y; Noguchi-Yachide T; Ishikawa M; Hashimoto Y
Bioorg Med Chem; 2013 Feb; 21(3):608-17. PubMed ID: 23276450
[TBL] [Abstract][Full Text] [Related]
55. [Screening and identification of Polo-like kinase 1 as a 14-3-3Zeta-interacting protein].
Du J; Cheng L; Chen LJ; Chen Y; An R
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Aug; 28(8):804-7. PubMed ID: 22863584
[TBL] [Abstract][Full Text] [Related]
56. Polo-like kinase-activating kinases: Aurora A, Aurora B and what else?
Archambault V; Carmena M
Cell Cycle; 2012 Apr; 11(8):1490-5. PubMed ID: 22433949
[TBL] [Abstract][Full Text] [Related]
57. Polo-like kinase 1 triggers the initiation of cytokinesis in human cells by promoting recruitment of the RhoGEF Ect2 to the central spindle.
Petronczki M; Glotzer M; Kraut N; Peters JM
Dev Cell; 2007 May; 12(5):713-25. PubMed ID: 17488623
[TBL] [Abstract][Full Text] [Related]
58. Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis.
Santamaria A; Neef R; Eberspächer U; Eis K; Husemann M; Mumberg D; Prechtl S; Schulze V; Siemeister G; Wortmann L; Barr FA; Nigg EA
Mol Biol Cell; 2007 Oct; 18(10):4024-36. PubMed ID: 17671160
[TBL] [Abstract][Full Text] [Related]
59. Bora and Aurora-A continue to activate Plk1 in mitosis.
Bruinsma W; Macurek L; Freire R; Lindqvist A; Medema RH
J Cell Sci; 2014 Feb; 127(Pt 4):801-11. PubMed ID: 24338364
[TBL] [Abstract][Full Text] [Related]
60. Playing polo during mitosis: PLK1 takes the lead.
Combes G; Alharbi I; Braga LG; Elowe S
Oncogene; 2017 Aug; 36(34):4819-4827. PubMed ID: 28436952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
